Sihuan Pharma - SHPHY STOCK NEWS

Welcome to our dedicated page for Sihuan Pharma news (Ticker: SHPHY), a resource for investors and traders seeking the latest updates and insights on Sihuan Pharma stock.

Sihuan Pharmaceutical Holdings Group Ltd, a global medical aesthetic and biopharmaceutical company, focuses on areas like medical aesthetics, oncology, diabetes, and more. Its innovative subsidiary, Xuanzhu Biopharmaceutical, recently obtained NMPA approval for Anaprozole Sodium Enteric-coated Tablet, a groundbreaking first-in-China proton pump inhibitor. This milestone marks the transition from R&D to commercialization, providing safe and effective treatment options for duodenal ulcer and potentially reflux esophagitis. With a strategic focus on innovation and global growth, Sihuan Pharmaceutical aims to become a leading company in the medical aesthetics and biopharmaceutical industry.

10/14/2023 08:09 AM

News

Sihuan Pharmaceutical Was Selected As One Of The First Echelon Of Enterprises In The list of China's Top 100 Pharmaceutical Innovative Enterprises in 2023

Rhea-AI Summary

Sihuan Pharmaceutical Holdings Group has been selected as one of the first echelon of enterprises in China's Top 100 Pharmaceutical Innovative Enterprises in 2023. The selection was based on patent data and aims to explore innovation power in the industry.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA

Rhea-AI Summary

Sihuan Pharmaceutical Holdings Group Ltd's subsidiary, Xuanzhu Biopharmaceutical Co., Ltd., has received drug registration approval from the NMPA of China for Anaprozole Sodium Enteric-coated Tablet. It is the first drug approved for marketing by Xuanzhu Biopharm and is used for the treatment of duodenal ulcer. The tablet is the first and only PPI fully developed in China and has fast onset, stable therapeutic effect, and low risk of drug interactions. It is also expanding its indication for the treatment of adult reflux esophagitis. The approval is expected to bring more treatment options for patients and inject billions of dollars into the acid suppressant market.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Sihuan Pharmaceutical（0460.HK）: Huisheng Biopharmaceutical Successfully Completed the A + Round of Financing

Rhea-AI Summary

Sihuan Pharmaceutical Holdings Group announced that its subsidiary, Huisheng Biopharmaceutical, completed an A+ round of financing, raising RMB580 million (approximately HK$650 million). This capital increase enhances Huisheng's registered capital to RMB372 million and values the company at RMB5.58 billion. The funds will be directed towards marketing and clinical advancements in diabetes treatment. Sihuan's share in Huisheng stands at approximately 61.29%, signaling investor confidence in its R&D capabilities and future prospects.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What areas does Sihuan Pharmaceutical focus on?

Sihuan Pharmaceutical focuses on high-growth therapeutic areas such as medical aesthetics, oncology, metabolism, diabetes, cardiovascular, cerebrovascular, modern Chinese medicine, and industrial hemp.

What recent achievement did Xuanzhu Biopharmaceutical reach?

Xuanzhu Biopharmaceutical obtained NMPA approval for Anaprozole Sodium Enteric-coated Tablet, the first proton pump inhibitor fully independently developed in China.

What are the main characteristics of Anaprozole Sodium Enteric-coated Tablet?

Anaprozole tablets effectively inhibit the secretion of gastric acid, have fast onset, stable therapeutic effect, low risk of drug interactions, and excretion through the gut and kidney for safer use in patients with renal insufficiency.

What is the strategic objective of Sihuan Pharmaceutical?

Sihuan Pharmaceutical's strategic objective is to promote a two-wheeled strategy of medical aesthetics and biopharmaceuticals to become a leading company in China.

What is the focus of Xuanzhu Biopharmaceutical?

Xuanzhu Biopharmaceutical focuses on major diseases like digestion, oncology, and non-alcoholic steatohepatitis, developing class 1 drugs with core proprietary intellectual property rights.

What are the R&D platforms of Xuanzhu Biopharmaceutical?

Xuanzhu Biopharmaceutical has two R&D platforms: small molecule chemistry and large molecule biologics, driving innovation and forming a broad product pipeline.

How does Sihuan Pharmaceutical drive innovation?

Sihuan Pharmaceutical is committed to continuous research and development, production, and commercialization of innovative drugs to address unmet clinical medical needs, focusing on international competitiveness.

What is the company's vision for the future?

The company aims to develop into a first-class innovative pharmaceutical company with independent research and development, production, and sales capabilities, serving human health with innovative drugs.

What is the market potential of Anaprozole Sodium Enteric-coated Tablet?

Anaprozole Sodium Enteric-coated Tablet has huge commercial potential and clinical value in the market due to its excellent clinical performance and acceptance by doctors and patients.